Amanda Lively
Payments from drug & device makers
Across 144 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$669
- AstraZeneca$475
- Lilly USA, LLC$159
- Novartis$147
- Pfizer$114
- Bayer$112
- plus $858 from 28 others
What the payments were for
- Food & beverage$2,535100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $669 |
| AstraZeneca | 28 | $475 |
| Lilly USA, LLC | 13 | $159 |
| Novartis | 9 | $147 |
| Pfizer | 6 | $114 |
| Bayer | 7 | $112 |
| Merck | 5 | $85 |
| Amgen | 4 | $72 |
| Amneal Pharmaceuticals LLC | 3 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Boehringer Ingelheim | 2 | $37 |
| Novo Nordisk | 2 | $35 |
| Organon | 2 | $33 |
| Biogen | 1 | $26 |
| Lundbeck LLC | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Boston Scientific | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Harmony Biosciences LLC | 1 | $18 |
| Medtronic | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Globus Medical | 1 | $15 |
How this compares
$2,535 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 21 | $24,055 |
| OzempicSemaglutide | 19 | $21,780 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $20,318 |
| MyrbetriqMirabegron | 18 | $11,689 |
| JardianceEmpagliflozin | 14 | $10,337 |
| XareltoRivaroxaban | 17 | $10,009 |
| BelsomraSuvorexant | 11 | $5,110 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 58 | $2,672 |
| Febuxostat | 14 | $2,301 |
| Citalopram HbrCitalopram Hydrobromide | 20 | $2,077 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,954 |
| Fentanyl | 13 | $1,832 |
| Omeprazole | 77 | $1,613 |
| Allopurinol | 18 | $1,544 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 35 | $1,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $159 | $24,05521 claims |
| Novo NordiskOzempic | $35 | $21,78019 claims |
| AstraZenecaBreztri Aerosphere | $475 | $20,31823 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $11,68918 claims |
| Boehringer IngelheimJardiance | $37 | $10,33714 claims |
| Johnson & JohnsonXarelto | $19 | $10,00917 claims |
| MerckBelsomra | $85 | $5,11011 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $57 | $1,052118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.
Other family in Price
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
- Shelby MillerSandy$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.